Organ-on-a-Chip Global Market - Forecast to 2026
Organ-on-a-Chips are AA battery sized microfluidic chips designed accurately to recreate the natural physiology and mechanical forces that cells experience in the human body. Organ-on-a-Chip is gaining popularity as they are rendered crucial for prognosis and monitor disease progression; personalized medicine along with playing a vital role in discovery and development of target molecules and drug toxicity testing also to cut cost and time of drug development.
According to IQ4I Research analysis, the Organ-on-a-Chip global market is estimated to reach $193,316.9 thousand by 2026 growing at a very high double digit CAGR from 2019 to 2026. The Organ-on-a-Chip market is classified into product, application, material type, end-user, and geography.
The factors driving the market are rising use of organ-on-a-chip in early detection of drug toxicity, increasing demand for personalized medicine, emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments for the development of different types of organ-on-a-chips, whereas, factors such as technical uncertainty within the pharma companies, the lack of scaling and standardization, biological and technical challenges involved are restraining the market growth.
The Organ-on-a-Chip product market is further classified into chips & services. The services segment accounted for the largest revenue in 2019. The Chips market is further segmented into liver, lung, kidney, tumor, multiple-organ-on-a-chip, and others. Among these, liver-on-a-chip accounted for the largest revenue in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The factors driving the market are increasing use of Liver-on-a-chip in drug discovery as a disease model (NASH) and also in toxicity screening of drugs, cosmetics, environmental pollutants, etc. The growth is also attributed to the increased interest shown by regulatory agencies, by the top pharma companies, other government organizations and venture capitalists for the development of the technology, whereas, factors such as lack of scaling and standards, the uncertainty of how regulatory bodies will adapt to technological changes, as OOC is in its infancy stage, they are still not efficient to replace the current methods followed, but, are used as an additional test for accuracy, complexity in the establishment of organ models, challenge to explore sample associated data requirement of ethical clarity, need for the establishment of well understood single mixed- cell models using universal media combined with the flow and supporting matrix are restraining the market growth.
Based on the application, the market is segmented into drug discovery, toxicity screening, and personalized medicine. Among these toxicity, screening accounted for the largest revenue of in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026 due to increased failure of drugs due to their toxicity had lead to the accelerated use of organ-on-a-chip involving human-derived cells to check their toxic effects. Further engagement of various chips in environmental toxicity testing, cosmetic toxicity is driving the growth of the market.
The market by material type is segmented into PDMS, polymers, glass, and silicon, among these, polymers commanded the largest revenue in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026. Factors such as ease of access and inexpensiveness, optically transparent, biocompatible, inert, rigidity are the factors favoring their usage. The silicon segment is expected to grow at a strong CAGR from 2019 to 2026.
Based on End-User, the market is segmented into Pharma & Biotech, Academic & research institutes, and other industries. Among the end-users, Pharma & Biotech accounted for the largest revenue in 2019 growing at a strong double digit CAGR from 2019 to 2026 due to extended research and development activities in biologics, drug development, and manufacturing.
Based on geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the world. Among these, the North American region dominated the Organ-On-A-Chip accounted for the largest revenue in 2019 growing at a high double digit CAGR from 2019 to 2026. This is due to the accelerated technological advancements in analytical and informatics field, presence of major players, increased funding from both private and government agencies, growing awareness about benefits of Organ-On-A-Chip in development of personalized medicine, presence of advanced research institutes with specialized technologies, pharma biotech companies, government & private agencies concentrating on accelerating Organ-on-a-Chip research. The Asia-Pacific region is the fastest-growing region with a strong CAGR from 2019 to 2026. This might be attributed to increasing government funding towards Organ-on-a-Chip research, and the emergence of this region as the manufacturing hub for biologics drugs.
Some of the companies are coming up with new technological advancements to maintain their leadership status in the Organ-on-a-Chip, for example, Mimetas BV launched assay ready product line: OrganoPlate Caco-2 which serves customer to receive a fully quality-controlled, ready-to-use tissue model to ADME, safety-, toxicology- and mechanistic studies for drug development, but also in the food and dairy industry.
The key players in Organ-on-a-Chip Global Market include Mimetas BV (The Netherlands), Emulate, Inc. (U.S), TissUse GmbH (Germany), Hesperos, Inc. (U.S.), Insphero AG. (Switzerland), CN Bio Innovations Ltd (U.K.), Nortis Inc ( U.S.), AlveoliX AG (Switzerland), Organovo Holdings, Inc. (U.S.) and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
According to IQ4I Research analysis, the Organ-on-a-Chip global market is estimated to reach $193,316.9 thousand by 2026 growing at a very high double digit CAGR from 2019 to 2026. The Organ-on-a-Chip market is classified into product, application, material type, end-user, and geography.
The factors driving the market are rising use of organ-on-a-chip in early detection of drug toxicity, increasing demand for personalized medicine, emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments for the development of different types of organ-on-a-chips, whereas, factors such as technical uncertainty within the pharma companies, the lack of scaling and standardization, biological and technical challenges involved are restraining the market growth.
The Organ-on-a-Chip product market is further classified into chips & services. The services segment accounted for the largest revenue in 2019. The Chips market is further segmented into liver, lung, kidney, tumor, multiple-organ-on-a-chip, and others. Among these, liver-on-a-chip accounted for the largest revenue in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The factors driving the market are increasing use of Liver-on-a-chip in drug discovery as a disease model (NASH) and also in toxicity screening of drugs, cosmetics, environmental pollutants, etc. The growth is also attributed to the increased interest shown by regulatory agencies, by the top pharma companies, other government organizations and venture capitalists for the development of the technology, whereas, factors such as lack of scaling and standards, the uncertainty of how regulatory bodies will adapt to technological changes, as OOC is in its infancy stage, they are still not efficient to replace the current methods followed, but, are used as an additional test for accuracy, complexity in the establishment of organ models, challenge to explore sample associated data requirement of ethical clarity, need for the establishment of well understood single mixed- cell models using universal media combined with the flow and supporting matrix are restraining the market growth.
Based on the application, the market is segmented into drug discovery, toxicity screening, and personalized medicine. Among these toxicity, screening accounted for the largest revenue of in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026 due to increased failure of drugs due to their toxicity had lead to the accelerated use of organ-on-a-chip involving human-derived cells to check their toxic effects. Further engagement of various chips in environmental toxicity testing, cosmetic toxicity is driving the growth of the market.
The market by material type is segmented into PDMS, polymers, glass, and silicon, among these, polymers commanded the largest revenue in 2019 and is expected to grow at a high double digit CAGR from 2019 to 2026. Factors such as ease of access and inexpensiveness, optically transparent, biocompatible, inert, rigidity are the factors favoring their usage. The silicon segment is expected to grow at a strong CAGR from 2019 to 2026.
Based on End-User, the market is segmented into Pharma & Biotech, Academic & research institutes, and other industries. Among the end-users, Pharma & Biotech accounted for the largest revenue in 2019 growing at a strong double digit CAGR from 2019 to 2026 due to extended research and development activities in biologics, drug development, and manufacturing.
Based on geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the world. Among these, the North American region dominated the Organ-On-A-Chip accounted for the largest revenue in 2019 growing at a high double digit CAGR from 2019 to 2026. This is due to the accelerated technological advancements in analytical and informatics field, presence of major players, increased funding from both private and government agencies, growing awareness about benefits of Organ-On-A-Chip in development of personalized medicine, presence of advanced research institutes with specialized technologies, pharma biotech companies, government & private agencies concentrating on accelerating Organ-on-a-Chip research. The Asia-Pacific region is the fastest-growing region with a strong CAGR from 2019 to 2026. This might be attributed to increasing government funding towards Organ-on-a-Chip research, and the emergence of this region as the manufacturing hub for biologics drugs.
Some of the companies are coming up with new technological advancements to maintain their leadership status in the Organ-on-a-Chip, for example, Mimetas BV launched assay ready product line: OrganoPlate Caco-2 which serves customer to receive a fully quality-controlled, ready-to-use tissue model to ADME, safety-, toxicology- and mechanistic studies for drug development, but also in the food and dairy industry.
The key players in Organ-on-a-Chip Global Market include Mimetas BV (The Netherlands), Emulate, Inc. (U.S), TissUse GmbH (Germany), Hesperos, Inc. (U.S.), Insphero AG. (Switzerland), CN Bio Innovations Ltd (U.K.), Nortis Inc ( U.S.), AlveoliX AG (Switzerland), Organovo Holdings, Inc. (U.S.) and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Need for early detection of drug toxicity
3.3.1.2 Increasing demand for personalized medicine
3.3.1.3 Emergence of ooc as an alternative to animal testing
3.3.1.4 significant increase in research funding and venture capital investments
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Technical uncertainty within the pharma companies
3.3.2.2 Lack of scaling and standardization
3.3.2.3 Biological and technical challenges
3.4 REGULATORY AFFAIRS
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 ASIA-PACIFIC
3.5 TECHNOLOGICAL ADVANCEMENTS
3.5.1 INTRODUCTION
3.5.2 HUMAN ON CHIP (BODY-ON-A-CHIP)
3.5.3 ORGANOID-ON-A-CHIP
3.5.4 PATIENT-ON-A-CHIP
3.5.5 AUTOMATION
3.5.6 ADVANCEMENT IN STEM CELL CULTURE
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 RIVALRY AMONG EXISTING COMPETITORS
3.6.4 BARGAINING POWER OF SUPPLIERS
3.6.5 BARGAINING POWER OF BUYERS
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7.1 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS
3.8 ORGAN-ON-A-CHIP UNITS SOLD
4 ORGAN-ON-A-CHIP GLOBAL MARKET, BY PRODUCTS
4.1 INTRODUCTION
4.2 CHIPS
4.2.1 LIVER-ON-A-CHIP
4.2.2 LUNG-ON-A-CHIP
4.2.3 KIDNEY-ON-A-CHIP
4.2.4 TUMOR-ON-A-CHIP
4.2.5 MULTI-ORGAN-ON-A-CHIP
4.2.6 OTHERS
4.2.6.1 Nerve-On-A-Chip
4.2.6.2 Heart-On-A-Chip
4.2.6.3 Skin-On-A-Chip
4.2.6.4 Blood Vessels-On-A-Chip
4.2.6.5 Intestine-On-A-Chip
4.2.6.6 Others (Blood-Brain Barrier-On-A-Chip, Lymphatic Vessel-On-A-Chip, Eye-On-A-Chip)
4.3 SERVICES
5 ORGAN-ON-A-CHIP GLOBAL MARKET, BY MATERIAL TYPE
5.1 INTRODUCTION
5.2 PDMS (POLY-DI-METHYL-SILOXANE)
5.3 POLYMERS
5.4 GLASS
5.5 SILICON
6 ORGAN-ON-A-CHIP GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 DRUG DISCOVERY
6.3 TOXICITY SCREENING
6.4 PERSONALIZED MEDICINE
7 ORGAN-ON-A-CHIP GLOBAL MARKET, BY END-USERS
7.1 INTRODUCTION
7.2 PHARMA BIOTECH
7.3 ACADEMICS AND RESEARCH INSTITUTES
7.4 OTHER INDUSTRIES
8 ORGAN-ON-A-CHIP GLOBAL MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA-PACIFIC
8.5 REST OF THE WORLD
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 AGREEMENTS AND COLLABORATIONS
9.3 NEW PRODUCT AND SERVICE LAUNCH
9.4 FUNDING
9.5 OTHERS
10 MAJOR COMPANIES
10.1 ALVEOLIX AG
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 CN BIO INNOVATIONS LTD.
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 EMULATE, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 HESPEROS, INC.
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 INSPHERO AG
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 MIMETAS B.V.
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 NORTIS, INC.
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 ORGANOVO HOLDINGS, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 SYNVIVO, INC.
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TARA BIOSYSTEMS, INC.
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
10.11 TISSUSE GMBH
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCT PORTFOLIO
10.11.4 KEY DEVELOPMENTS
10.11.5 BUSINESS STRATEGY
10.11.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Need for early detection of drug toxicity
3.3.1.2 Increasing demand for personalized medicine
3.3.1.3 Emergence of ooc as an alternative to animal testing
3.3.1.4 significant increase in research funding and venture capital investments
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Technical uncertainty within the pharma companies
3.3.2.2 Lack of scaling and standardization
3.3.2.3 Biological and technical challenges
3.4 REGULATORY AFFAIRS
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 ASIA-PACIFIC
3.5 TECHNOLOGICAL ADVANCEMENTS
3.5.1 INTRODUCTION
3.5.2 HUMAN ON CHIP (BODY-ON-A-CHIP)
3.5.3 ORGANOID-ON-A-CHIP
3.5.4 PATIENT-ON-A-CHIP
3.5.5 AUTOMATION
3.5.6 ADVANCEMENT IN STEM CELL CULTURE
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 RIVALRY AMONG EXISTING COMPETITORS
3.6.4 BARGAINING POWER OF SUPPLIERS
3.6.5 BARGAINING POWER OF BUYERS
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7.1 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS
3.8 ORGAN-ON-A-CHIP UNITS SOLD
4 ORGAN-ON-A-CHIP GLOBAL MARKET, BY PRODUCTS
4.1 INTRODUCTION
4.2 CHIPS
4.2.1 LIVER-ON-A-CHIP
4.2.2 LUNG-ON-A-CHIP
4.2.3 KIDNEY-ON-A-CHIP
4.2.4 TUMOR-ON-A-CHIP
4.2.5 MULTI-ORGAN-ON-A-CHIP
4.2.6 OTHERS
4.2.6.1 Nerve-On-A-Chip
4.2.6.2 Heart-On-A-Chip
4.2.6.3 Skin-On-A-Chip
4.2.6.4 Blood Vessels-On-A-Chip
4.2.6.5 Intestine-On-A-Chip
4.2.6.6 Others (Blood-Brain Barrier-On-A-Chip, Lymphatic Vessel-On-A-Chip, Eye-On-A-Chip)
4.3 SERVICES
5 ORGAN-ON-A-CHIP GLOBAL MARKET, BY MATERIAL TYPE
5.1 INTRODUCTION
5.2 PDMS (POLY-DI-METHYL-SILOXANE)
5.3 POLYMERS
5.4 GLASS
5.5 SILICON
6 ORGAN-ON-A-CHIP GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 DRUG DISCOVERY
6.3 TOXICITY SCREENING
6.4 PERSONALIZED MEDICINE
7 ORGAN-ON-A-CHIP GLOBAL MARKET, BY END-USERS
7.1 INTRODUCTION
7.2 PHARMA BIOTECH
7.3 ACADEMICS AND RESEARCH INSTITUTES
7.4 OTHER INDUSTRIES
8 ORGAN-ON-A-CHIP GLOBAL MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA-PACIFIC
8.5 REST OF THE WORLD
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 AGREEMENTS AND COLLABORATIONS
9.3 NEW PRODUCT AND SERVICE LAUNCH
9.4 FUNDING
9.5 OTHERS
10 MAJOR COMPANIES
10.1 ALVEOLIX AG
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 CN BIO INNOVATIONS LTD.
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 EMULATE, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 HESPEROS, INC.
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 INSPHERO AG
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 MIMETAS B.V.
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 NORTIS, INC.
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 ORGANOVO HOLDINGS, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 SYNVIVO, INC.
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TARA BIOSYSTEMS, INC.
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
10.11 TISSUSE GMBH
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCT PORTFOLIO
10.11.4 KEY DEVELOPMENTS
10.11.5 BUSINESS STRATEGY
10.11.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 2 ORGAN-ON-A-CHIP UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2018-2026)(NO.)
TABLE 3 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 4 CHIPS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 5 CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 6 LIVER-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 7 LUNG-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 8 KIDNEY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 9 TUMOR-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 10 MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 11 OTHER CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($MN)
TABLE 12 OTHER ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 13 SELECTED ORGAN-ON-A-CHIP COMPANIES (ORGAN MATRIX OR PRODUCT & SERVICE OFFERINGS)
TABLE 14 SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 15 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY MATERIAL TYPE (2018-2026) ($’000S)
TABLE 16 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 17 DRUG DISCOVERY GLOBAL MARKET REVENUE, BY REGION (2019-2026) ($’000S)
TABLE 18 TOXICITY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 19 PERSONALIZED MEDICINE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 20 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 21 PHARMA BIOTECH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 22 ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 23 OTHER INDUSTRIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 24 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 25 NORTH AMERICA CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 26 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 27 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 28 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 29 EUROPE CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 30 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 31 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 32 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 33 ASIA-PACIFIC CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 34 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 35 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 36 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 37 REST OF THE WORLD CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 38 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 39 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 40 AGREEMENTS & COLLABORATIONS (2018-2020)
TABLE 41 NEW PRODUCT AND SERVICE LAUNCH (2018-2020)
TABLE 42 FUNDING (2018-2020)
TABLE 43 OTHERS (2018-2020)
TABLE 44 ORGANOVO HOLDINGS, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3)($MN)
TABLE 45 ORGANOVO HOLDINGS, INC.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 1 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 2 ORGAN-ON-A-CHIP UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2018-2026)(NO.)
TABLE 3 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 4 CHIPS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 5 CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 6 LIVER-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 7 LUNG-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 8 KIDNEY-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 9 TUMOR-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 10 MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 11 OTHER CHIPS GLOBAL MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($MN)
TABLE 12 OTHER ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 13 SELECTED ORGAN-ON-A-CHIP COMPANIES (ORGAN MATRIX OR PRODUCT & SERVICE OFFERINGS)
TABLE 14 SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 15 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY MATERIAL TYPE (2018-2026) ($’000S)
TABLE 16 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 17 DRUG DISCOVERY GLOBAL MARKET REVENUE, BY REGION (2019-2026) ($’000S)
TABLE 18 TOXICITY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 19 PERSONALIZED MEDICINE GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 20 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 21 PHARMA BIOTECH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 22 ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 23 OTHER INDUSTRIES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
TABLE 24 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 25 NORTH AMERICA CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 26 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 27 NORTH AMERICA ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 28 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 29 EUROPE CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 30 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 31 EUROPE ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 32 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 33 ASIA-PACIFIC CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 34 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 35 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 36 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY PRODUCT (2018-2026) ($’000S)
TABLE 37 REST OF THE WORLD CHIPS MARKET REVENUE, BY ORGAN TYPE (2018-2026) ($’000S)
TABLE 38 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY APPLICATION (2018-2026) ($’000S)
TABLE 39 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET REVENUE, BY END-USER (2018-2026) ($’000S)
TABLE 40 AGREEMENTS & COLLABORATIONS (2018-2020)
TABLE 41 NEW PRODUCT AND SERVICE LAUNCH (2018-2020)
TABLE 42 FUNDING (2018-2020)
TABLE 43 OTHERS (2018-2020)
TABLE 44 ORGANOVO HOLDINGS, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3)($MN)
TABLE 45 ORGANOVO HOLDINGS, INC.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
LIST OF FIGURES
FIGURE 1 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
FIGURE 2 RESEARCH METHODOLOGY: ORGAN-ON-A-CHIP GLOBAL MARKET
FIGURE 3 ORGAN-ON-A-CHIP GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 ORGAN-ON-A-CHIP GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 ORGAN-ON-A-CHIP GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 ORGAN-ON-A-CHIP GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 ORGAN-ON-A-CHIP GLOBAL MARKET: PORTER’S FIVE FORCE ANALYSIS
FIGURE 9 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
FIGURE 10 ORGAN-ON-A-CHIO UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2019 VS 2026) (NO’S)
FIGURE 11 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
FIGURE 12 ORGAN-ON-A-CHIP PRODUCTS AND SERVICES COMPANIES
FIGURE 13 CHIPS GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 14 CHIPS GLOBAL MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 15 LIVER-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 16 LUNG-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 17 KIDNEY-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 18 TUMOR-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 19 MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 20 OTHERS-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 21 SELECTED COMPANIES AND THEIR PRODUCT & SERVICE OFFERING
FIGURE 22 SERVICES GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 23 ORGAN-0N-A-CHIP GLOBAL MARKET SHARE, BY MATERIAL TYPE (2019 VS 2026) (%)
FIGURE 24 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 25 DRUG DISCOVERY GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 26 TOXICITY SCREENING GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 27 PERSONALIZED MEDICINE GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 28 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 29 PHARMA BIOTECH GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 30 ACADEMICS AND RESEARCH INSTITUTE GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 31 OTHER INDUSTRIES GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 32 NORTH AMERICA ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 33 NORTH AMERICA CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 34 NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 35 NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 36 EUROPE ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 37 EUROPE CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 38 EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 39 EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 40 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 41 ASIA-PACIFIC CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 42 ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 43 ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 44 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 45 REST OF THE WORLD CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 46 REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 47 REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 48 KEY GROWTH STRATEGIES (2018-2020)
FIGURE 49 SWOT: ALVEOLIX AG
FIGURE 50 SWOT: CN BIO INNOVATIONS LTD.
FIGURE 51 SWOT: EMULATE, INC.
FIGURE 52 SWOT: HESPEROS, INC.
FIGURE 53 SWOT: INSPHERO AG
FIGURE 54 SWOT: MIMETAS B. V.
FIGURE 55 SWOT: NORTIS, INC.
FIGURE 56 SWOT: ORGANOVO HOLDINGS, INC.
FIGURE 57 SWOT: SYNVIVO, INC.
FIGURE 58 SWOT: TARA BIOSYSTEMS, INC.
FIGURE 59 SWOT: TISSUSE GMBH
FIGURE 1 ORGAN-ON-A-CHIP GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($’000S)
FIGURE 2 RESEARCH METHODOLOGY: ORGAN-ON-A-CHIP GLOBAL MARKET
FIGURE 3 ORGAN-ON-A-CHIP GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 ORGAN-ON-A-CHIP GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 ORGAN-ON-A-CHIP GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 ORGAN-ON-A-CHIP GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 ORGAN-ON-A-CHIP GLOBAL MARKET: PORTER’S FIVE FORCE ANALYSIS
FIGURE 9 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
FIGURE 10 ORGAN-ON-A-CHIO UNITS SOLD BY CHIP COMPANIES AND SERVICE PROVIDERS (2019 VS 2026) (NO’S)
FIGURE 11 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
FIGURE 12 ORGAN-ON-A-CHIP PRODUCTS AND SERVICES COMPANIES
FIGURE 13 CHIPS GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 14 CHIPS GLOBAL MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 15 LIVER-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 16 LUNG-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 17 KIDNEY-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 18 TUMOR-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 19 MULTI-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 20 OTHERS-ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 21 SELECTED COMPANIES AND THEIR PRODUCT & SERVICE OFFERING
FIGURE 22 SERVICES GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 23 ORGAN-0N-A-CHIP GLOBAL MARKET SHARE, BY MATERIAL TYPE (2019 VS 2026) (%)
FIGURE 24 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 25 DRUG DISCOVERY GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 26 TOXICITY SCREENING GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 27 PERSONALIZED MEDICINE GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 28 ORGAN-ON-A-CHIP GLOBAL MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 29 PHARMA BIOTECH GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 30 ACADEMICS AND RESEARCH INSTITUTE GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 31 OTHER INDUSTRIES GLOBAL MARKET SHARE, BY REGION (2019) (%)
FIGURE 32 NORTH AMERICA ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 33 NORTH AMERICA CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 34 NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 35 NORTH AMERICA ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 36 EUROPE ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 37 EUROPE CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 38 EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 39 EUROPE ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 40 ASIA-PACIFIC ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 41 ASIA-PACIFIC CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 42 ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 43 ASIA-PACIFIC ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 44 REST OF THE WORLD ORGAN-ON-A-CHIP MARKET SHARE BY PRODUCT (2019 VS 2026) (%)
FIGURE 45 REST OF THE WORLD CHIPS MARKET SHARE, BY ORGAN TYPE (2019 VS 2026) (%)
FIGURE 46 REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 47 REST OF THE WORLD ORGAN-0N-A-CHIP MARKET SHARE, BY END-USER (2019 VS 2026) (%)
FIGURE 48 KEY GROWTH STRATEGIES (2018-2020)
FIGURE 49 SWOT: ALVEOLIX AG
FIGURE 50 SWOT: CN BIO INNOVATIONS LTD.
FIGURE 51 SWOT: EMULATE, INC.
FIGURE 52 SWOT: HESPEROS, INC.
FIGURE 53 SWOT: INSPHERO AG
FIGURE 54 SWOT: MIMETAS B. V.
FIGURE 55 SWOT: NORTIS, INC.
FIGURE 56 SWOT: ORGANOVO HOLDINGS, INC.
FIGURE 57 SWOT: SYNVIVO, INC.
FIGURE 58 SWOT: TARA BIOSYSTEMS, INC.
FIGURE 59 SWOT: TISSUSE GMBH
